This meta-analysis provides the evidence that the reduction of office systolic blood
Azilsartan medoxomil (AZL-M), a novel angiotensin receptor blocker, lowers blood
Taking telmisartan more significantly reduced the 24-h BP in the morning compared with
Azilsartan medoxomil (AZL-M), a novel angiotensin receptor blocker, lowers blood pressure (BP) more effectively than olmesartan (OLM) and valsartan (VAL) in patients with hypertension
Olmesartan, an angiotensin II type 1 receptor antagonist (ARB) first approved in 2002, is commonly used for the treatment of hypertension
We randomly assigned patients to changeover from their prior ARBs to either azilsartan or olmesartan, and followed the patients for 3 months
We performed this meta-analysis determining the antihypertensive effect of azilsartan versus olmesartan in patients with essential
2019 May;188(2):481-488
5 out of 10 from a total of 568 ratings on Drugs
Similar results to the primary analysis were seen for both 24-hour mean diastolic BP (DBP) and clinic Another double-blind, randomized, placebo-controlled trial13 compared azilsartan with olmesartan and valsartan
Side effects:Taking olmesartan comes with a small risk of “sprue-like enteropathy
In this study, azilsartan was well tolerated and more efficacious at its maximal dose than the highest dose of olmesartan medoxomil [ 14 ]
olmesartan medoxomil is hydrolyzed by several esterase enzymes in the intestines releasing the proportion of patients was comparable with (olmesartan 2
ramipril 3
They suspected that the effect on glomerular efferent arterioles in the azilsartan group might be stronger than that in the olmesartan group
There were 413 patients, with a mean age of